Status:
ACTIVE_NOT_RECRUITING
Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study
Lead Sponsor:
Peking University Third Hospital
Collaborating Sponsors:
National Natural Science Foundation of China
Ministry of Education, China
Conditions:
Osteoporosis，Neurological Disorders
Eligibility:
All Genders
55-105 years
Brief Summary
Epigenetic modification refers to the change of heritable gene expression occurring in the case of unchanged DNA sequence, including DNA methylation, epigenetic modification, RNAS, chromatin modificat...
Eligibility Criteria
Inclusion
- Normal hearing, vision, and pronunciation
- DEXA examination
Exclusion
- Mental retardation
- Blindness, deafness, and dumb
- Severe schizophrenia
Key Trial Info
Start Date :
September 21 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 22 2027
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT03401619
Start Date
September 21 2017
End Date
September 22 2027
Last Update
September 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191